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SObjectives: Intramucosal esophageal cancer treatment is evolving. Less-invasive therapies have emerged,
necessitating review of safety, effectiveness, and determinants of long-term outcome after esophagectomy to
clarify the role of this traditional, maximally invasive, and potentially harmful therapy.
Methods: From January 1983 to January 2011, 164 patients underwent esophagectomy alone for intramucosal
adenocarcinoma. Cancers were subdivided by depth of invasion: lamina propria 50 (30%) and muscularis mu-
cosa 114 (70%; inner 42 [26%], middle 16 [10%], and outer 56 [34%]). We assessed complications and
esophagectomy-related mortality (safety) and cancer recurrence (effectiveness), and identified determinants
of long-term outcomes.
Results: Barrett esophagus (P ¼ .005), larger cancers (P<.001), worse histologic grade (P<.001), lympho-
vascular invasion (P<.001), and overstaging (P ¼ .02) were associated with deeper cancers. One patient had
regional lymph node metastases (0.6%). Seventy-five patients (46%) had complications. Seven of 9 deaths
within 6 months were esophagectomy related, 6 from respiratory failure. Seven patients had recurrence, all
within 4 years. Five-, 10-, and 15-year survivals were 82%, 69%, and 60%, respectively, which were similar
to those of a matched general population. Determinants of late mortality were older age (P ¼ .004), poorer
lung function (P< .0001), longer cancer (P ¼ .04), postoperative pneumonia (P ¼ .06), cancer recurrence
(P<.0001), and second cancers (P<.0001).
Conclusions: Survival after esophagectomy for intramucosal adenocarcinoma is excellent, determined more by
patient than cancer characteristics. Patient selection and respiratory function are crucial to minimize harm. Con-
sidering the outcome of emerging therapies, esophagectomy should be reserved for patients with a long intra-
mucosal adenocarcinoma or those in whom endoscopic therapies fail or are inappropriate. (J Thorac Cardiovasc
Surg 2013;145:1519-24)Supplemental material is available online.Intramucosal esophageal adenocarcinoma treatment is
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outcome.PATIENTS AND METHODS
Patients
From January 1983 to January 2011, 1357 patients underwent esopha-
gectomy for cancer at Cleveland Clinic (Appendix E1). Of these patients,
164 had a pathologic diagnosis of adenocarcinoma invading the mucosae
but not beyond (pT1a). All patients had esophagectomy alone without in-
duction therapy. The esophagectomy database used for this study was ap-
proved for use in research by the institutional review board, with patient
consent waived.
Patients were predominantly elderly white men with hiatal hernia
(87%) and Barrett esophagus (92%) (Table 1); 38% were in a Barrett sur-
veillance program. Lung function varied widely, and 13% of patients had
a prior nonesophageal malignancy.
Cancer Characteristics
Clinical stage was determined by biopsy at esophagogastroduodeno-
scopy in 164 patients, with additional esophageal ultrasound staging in
88 patients (54%). Clinical stage was clinical high-grade dysplasia
(HGD) in 28 patients (17%), cT1aN0 in 115 patients (70%), and greater
than cT1N0 in 21 patients (13%) (Table 1). Ninety-eight percent of cancers
(n ¼ 161) were located in the lower thoracic esophagus. Cancers were
small, with a median length at esophagogastroduodenoscopy of 0.8 cm
and width of 0.4 cm. Pathologic re-review was performed by 2diovascular Surgery c Volume 145, Number 6 1519
Abbreviation and Acronym
HGD ¼ high-grade dysplasia
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grade, presence of lymphovascular invasion, and number of positive nodes
were assessed. One patient was found to have 6 positive nodes (pN2). How-
ever, 14% of patients had definite or possible lymphovascular invasion. No
patient had distant metastasis. The majority of cancers were moderate or
well differentiated (85%).
Esophagectomy
Sixty-eight percent of patients (n¼ 111) underwent a transhiatal esoph-
agectomy, and 32% underwent a thoracotomy.1 All cancer margins were
R0, except in 1 patient who had Barrett esophagus without dysplasia at
the proximal margin. The median number of lymph nodes sampled was 12.
Outcomes
Safety was assessed by the combination of postoperative complications
(Table 2), operative mortality (deaths in hospital or within 30 days of
esophagectomy), and deaths in the first 6 months attributed to esophagec-
tomy (esophagectomy related). Effectiveness was assessed by esophageal
cancer recurrence and all-cause mortality referenced to an age-, race-,
and sex-matched US population. Determinants of long-term outcome
were based on cancer recurrence, all-cause mortality, and second noneso-
phageal cancer.
Active follow-up for vital status, cancer recurrence, and second cancers
was complete to January 2010 in 156 patients (95%) and to January 2011 in
104 patients (63%). Median follow-upwas 85months, and 10% of patients
were followed more than 14 years. For survival, time relatedness of cancer
recurrence, all-cause mortality, and second cancers were estimated by the
nonparametric time-related Kaplan–Meier method and parametrically us-
ing multiphase hazard modeling.2 (For additional details, see http://my.
clevelandclinic.org/professionals/software/hazard/default.aspx.) Overall
survival was referenced to an age-, race-, and sex-specific US population.
Determinants of long-term outcomes were identified for cancer recur-
rence, all-cause mortality, and second cancers, and for each hazard phase
simultaneously using variables listed in Table 1 and detailed in Appendix
E2. Variable selection used bagging.3,4 Briefly, automated stepwise
variable selection was performed on 1000 bootstrap samples, and
frequency of occurrence of variables related to procedure performed was
ascertained by themedian rule.3 For all-causemortality, analysis proceeded
sequentially. First, only preoperative patient and cancer characteristics
were entered into the analysis. This was followed by these plus details of
the operation and then of postoperative complications. Finally, esophageal
cancer recurrence and second cancer, and time to their diagnosis, were en-
tered as time-varying covariables.
Presentation
Continuous variables are summarized as mean  1 standard deviation
for normally distributed variables and as equivalent median, 15th, and
85th percentiles when values are skewed. Categoric variables are summa-
rized as frequency and percentage. Time-related estimates are accompa-
nied by 68% confidence limits equivalent to 1 standard error.RESULTS
Safety
Mortality. Three patients (1.8%) died in hospital, and 2
patients (1.2%) died within 30 days of esophagectomy.
Nine deaths occurred within 6 months, 7 of which were1520 The Journal of Thoracic and Cardiovascular Suresophagectomy related, resulting in an actuarial survival
of 95% at 6 months. These deaths were from respiratory
failure in 6 patients and accompanied by renal failure in
3. The seventh patient died of superior mesenteric artery
thrombosis.
Complications. Seventy-five patients (46%) experienced
125 complications (Table 3). Themost commonwerewound
(22%), cardiovascular (21%), and respiratory (20%).
Effectiveness
Cancer recurrence. Seven patients had esophageal cancer
recurrence, all within 4 years of esophagectomy (Figure 1),
3 locoregional and 4 distant. One patient is alive 43 months
after esophagectomy, and 6 patients died 13 to 58 months
after esophagectomy (4-44 months after recurrence).
All-cause mortality. Five-, 10-, and 15-year survivals
were 82%, 69%, and 60%, respectively (Figure 2). These
cancer patients had a higher risk of death after esophagec-
tomy than a matched US population (Figure 2), but after 9
months, risk was similar.
Determinants of Long-Term Outcome
Preoperative. No predictors of early mortality were iden-
tified because of the small number of postoperative events.
Operative mortality was similar across the experience.
Patient characteristics associated with mortality included
older age at esophagectomy and poorer lung function
(Table 4 and Figure E1). The only cancer characteristic
associated with mortality was length. However, there was
interplay among cancer characteristics. Barrett esophagus,
deeper invasion of the mucosa, worse histologic grade, lym-
phovascular invasion, and overstaging were associated with
larger cancers (Table E1 and Figure E2).
Operative details. No operative feature was a risk factor.
Postoperative. Respiratory complications, particularly
pneumonia, increased the risk of mortality (Table 4).
Time-related factors. Cancer recurrence and second non-
esophageal cancers (Figure 3) were risk factors for late mor-
tality (Table 4). The following cancers developed in 20
patients: 23 second nonesophageal malignancies, 10 genito-
urinary (6 prostate, 3 kidney, 1 bladder), 3 lung, 3 colorec-
tal, 3 skin, and 1 each head and neck, brain, pancreas, and
duodenum. Eight patients have died—6 with second nones-
ophageal malignancies, 1 with pre-esophagectomy mela-
noma, and 1 of a non–cancer-related cause.
DISCUSSION
Intramucosal esophageal adenocarcinoma is truly an
early cancer because it is locally confined and rarely
metastasizes to lymph nodes. Esophagectomy cures 95%
of patients. However, risk of cancer recurrence is approxi-
mately equal to risk of death from esophagectomy. There-
fore, it is critical to do no harm in treating patients with
this good prognosis, but this maximally invasive proceduregery c June 2013
TABLE 1. Patient and cancer characteristics (n ¼ 164)
Characteristics n* Value
Patient
Age (y) 164
Mean  SD 63  10
Median (range) 64 (35-82)
Gender 164
Male 142 (87)
Female 22 (13)
Race 164
White 161 (98)
Black 2 (1.2)
Hispanic 1 (0.6)
FEV1 (% of predicted) 149
Mean  SD 92  18
Median (range) 92 (35-136)
FVC (% of predicted) 148
Mean  SD 98  16
Median (range) 96 (57-158)
Pathologic Barrett esophagus 164
Yes 151 (92)
No 13 (7.9)
Pathologic Barrett length (cm) 115
Mean  SD 4.6  3.1
Median (range) 4.5 (0-12)
Hiatal hernia 164
Yes 143 (87)
No 21 (13)
Hiatal hernia length (cm) 164
Mean  SD 3.0  2.0
Median (range) 3.0 (0-11)
Cancer
Clinical stagey 164
cHGD 28 (17)
cT1N0 115 (70)
>cT1N0 21 (13)
Depth of invasion 164
LP 50 (30)
MM1 (inner) 42 (26)
MM2 (between) 16 (9.8)
MM3 (outer) 56 (34)
Tumor length on pathology (cm) 156
Median (range) 0.70 (0.10-5.9)
Histologic grade 164
G1 55 (34)
G2 83 (51)
G3 26 (16)
Lymphovascular invasion 154
Yes 6 (3.9)
Possible 15 (9.7)
No 133 (86)
No. of lymph nodes sampled 164
Median (range) 12 (0-56)
No. of positive nodes 164
0 163 (99)
6 1 (0.60)
SD, Standard deviation; FEV1, forced expiratory volume in 1 second; FVC, forced vi-
tal capacity; cHGD, clinical high-grade dysplasia; LP, lamina propria;MM,muscula-
ris mucosa. *Patients with data available. yEndoscopic ultrasound and preoperative
biopsy.
TABLE 2. Definition of complications
Wound
Anastomotic leak: Detection of saliva, ingestedmaterial, gastric secretions,
or bile in the drain or wound. Radiographic confirmation was not
required.
Infection: Local findings of erythema, drainage, subcutaneous emphysema,
or tenderness requiring wound opening with positive wound culture.
Pulmonary
Pneumonia: Radiographic confirmation with positive respiratory tract
culture.
Respiratory failure: Reintubation or tracheostomy for weaning failure.
Vocal cord paralysis: Laryngoscopy confirmation required.
Pneumothorax: Radiographic confirmation requiring chest tube
reinsertion.
Pleural effusion: Pleural effusion after chest tube removal requiring chest
tube reinsertion or thoracentesis.
Cardiovascular
Electrocardiographic confirmation of atrial arrhythmia.
Ultrasound confirmation of deep venous thrombosis.
Neurologic
Delirium: Transient confusion confirmed by disturbances in consciousness,
cognition, and perception.
Li et al General Thoracic Surgery
The Journal of Thoracic and Car
G
T
Sis associated with postoperative complications in nearly
50% of patients, and these contribute to the death of 5%
of patients in the first 6 months after surgery. Endoscopic
therapy also may do harm because it is not totally safe
and is not as effective in curing cancer. This has led us to
examine the technical success, safety, and clinical effective-
ness of these treatment options.
Success
Technical success is the ability to locally eliminate can-
cer and precursor intestinal metaplasia. In this series of
164 patients, all had R0 resections for cancer and 163 had
R0 resections for Barrett metaplasia. Intestinal metaplasiaTABLE 3. Postoperative complications
Type
No. of
complications
No. of
patients % of 164
Wound 36 36 22
Anastomotic leak 9 9 5.5
Infection 27 27 16
Respiratory 42 32 20
Pneumonia 6 6 3.7
Respiratory failure 20 20 12
Vocal cord paralysis 5 5 3.0
Pneumothorax 1 1 0.6
Pleural effusion 10 10 6.1
Cardiovascular 36 35 21
Atrial arrhythmia 26 16
Deep vein thrombosis 10 6.1
Neurologic
Delirium 11 11 6.7
Total 125 75*
*Many patients had multiple complications.
diovascular Surgery c Volume 145, Number 6 1521
FIGURE 1. Recurrence of cancer after esophagectomy for intramucosal
cancer. Each circle represents a recurrence, vertical bars represent 68%
confidence limits, and numbers in parentheses represent patients remaining
at risk. Solid line enclosed within dashed 68% confidence band represents
parametric estimate. Instantaneous risk of recurrence (hazard function)
peaks at 15 months. There was no recurrence after 37 months.
TABLE 4. Incremental risk factors for mortality after esophagectomy
for intramucosal cancer: Sequential analysis
Risk factor Coefficient ± SD P
Reliability
(%)*
1. Patient and cancer characteristics, operative details
Older age (y)y 0.75  0.24 .002 80
Lower FVC (% of
predicted)z
3.2  0.52 <.0001 96
Longer cancer (cm)x 0.060  0.024 .01 89
2. Add postoperative complications
Older age (y)y 0.76  0.24 .001 76
Lower FVC (% of
predicted)z
3.3  0.52 <.0001 94
Longer cancer (cm)x 0.062  0.023 .008 88
Postoperative pneumonia 1.3  0.67 .05 55
3. Add recurrence and second cancers
Older age (y)y 0.58  0.20 .004 59
Lower FVC (% of
predicted)z
3.2  0.51 <.0001 94
Longer cancer (cm)x 0.051  0.025 .04 90
Postoperative pneumonia 1.1  0.58 .06 67
Cancer recurrence 2.5  0.46 <.0001 99.6
Longer interval to second
cancer (y)
0.27  0.048 <.0001 98.9
No risk factors were identified in the early hazard phase. SD, Standard deviation;
FVC, forced vital capacity. *Percent of times factor appeared in 1000 bootstrap
models. yExp (age/50), exponential transformation. z(81/FVC)2, inversed squared
transformation. xLength2, squared transformation.
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Safter a cervical esophagogastrostomy develops in few
patients (16% at 5 years), and dysplasia and cancer
are rare.1 Inflammatory changes at the anastomosis can be
lessened by construction of a high anastomosis and
proton-pump inhibitor therapy.
Endoscopic mucosal resection or ablative therapy is less
likely to be technically successful than esophagectomy. In
a study by Pech and colleagues5 of 486 patients with clinical
HGD or intramucosal cancer, 279 underwent endoscopic
mucosal resection, 55 received photodynamic ablative ther-
apy, and 13 received both.5 Ninety-six percent of patients
had a ‘‘complete response,’’ but 3.6% required esophagec-
tomy for technical failures. At a median of 15 months (25th
percentile 12 months, 75th percentile 24 months), 22% ofFIGURE 2. Survival after esophagectomy for intramucosal cancer. For-
mat is as in Figure 1 except that the age-, race-, and sex-matched US pop-
ulation life table is superimposed (dash-dot-dash line). Instantaneous risk
of death (hazard function) peaks early after operation and then decreases to
a constant level similar to that of the general population.
1522 The Journal of Thoracic and Cardiovascular Surpatients had HGD or cancer. Predictors of recurrence
were piecemeal resection, long-segment Barrett esophagus,
no ablative therapy after complete response, more than 10
months required to achieve complete response, and multifo-
cal neoplasia. Among 341 patients studied by Pouw and col-
leagues,6 169 underwent endoscopic resection of early
Barrett neoplasia at 4 centers. At the end of treatment,
98% had eradication of neoplasia and 85% had eradication
of metaplasia. Two patients (2.4%) required surgery for im-
mediate technical failures or complications. At a median of
32 months (interquartile range, 19-49 months), 95% ofFIGURE 3. Freedom from second nonesophageal cancer after esophagec-
tomy for intramucosal cancer. Depiction is as in Figure 1.
gery c June 2013
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tion of metaplasia, with 9 patients (5.3%) requiring re-
treatment during follow-up.
Ablative therapy has been reported typically for Barrett
metaplasia and dysplasia but not for intramucosal cancer.
Unlike esophagectomy, but like endoscopic resection, abla-
tive therapy is less likely to eradicate Barrett metaplasia and
dysplasia. Lyday and colleagues7 studied 429 treated pa-
tients who had Barrett metaplasia with or without dysplasia.
In 1 cohort, 338 patients had at least 1 biopsy session after
ablation, with 72% free of Barrett metaplasia and 89% free
of dysplasia. In another cohort of 137 patients with at least 1
session a year or more after therapy, 77%were free of meta-
plasia and 100% were free of dysplasia.7 Among 50 pa-
tients with nondysplastic Barrett esophagus reported by
Fleischer and colleagues,8 freedom from metaplasia after
radiofrequency ablation was 91% (95% confidence inter-
val, 77%-97%) at 4 years. Shaheen and colleagues9 re-
ported that 77% of patients had eradication of metaplasia
and 81% had eradication of dysplasia 12 months after abla-
tion of dysplastic Barrett esophagus.
Safety
Safety is freedom from risk and can be assessed by
complications and death after treatment. Although esopha-
gectomy can be performed with a 30-day in-hospital
mortality of approximately 1%, longer follow-up demon-
strates that it is associated with late death. It can be expected
that approximately 50% of patients will experience a com-
plication after esophagectomy.
Treatment mortality is rarely reported after endoscopic
therapy, and complications are less frequent than after
esophagectomy by approximately half.10 Pech and col-
leagues5 reported complications in 17% of patients after
endoscopic mucosal resection. In other studies, complica-
tions occurred in 3.6%7 and 2.3%9 of patients receiving
ablation, with strictures reported in 6%9 and 2.1%.7
Clinical Effectiveness
Clinical effectiveness is the ability to cure cancer. Al-
though overall survival is generally similar after esophagec-
tomy or endoscopic therapy,11-13 cancer-free survival is
worse after endoscopic therapy. Recurrence after esopha-
gectomy is uncommon, and if it occurs, it does so early after
surgery, whereas after ablative therapy, recurrence is a later
and continuing problem. Prasad and colleagues12 reported
5-year cancer-free survival of 97% after esophagectomy
and 80% after endoscopic therapy (P ¼ .01). Schembre
and colleagues13 reported no cancer recurrences after a me-
dian follow-up of 48 months in 32 patients undergoing
esophagectomy, despite identifying previously unrecog-
nized cancer in 25% of the resection specimens; cancer re-
currence developed at a median of 20 months of follow-up
in 6% of 62 patients receiving endoscopic therapy.13The Journal of Thoracic and CarStrengths and Limitations
A limitation of this study is that it is a large, single-
institution experience covering more than 25 years. How-
ever, this is also a strength because of availability of
a large volume of long-term data on intramucosal esoph-
ageal adenocarcinoma. The patients represent a highly
selected referral population. The only outcomes studied
were survival, cancer recurrence, and second primary can-
cer; quality of life was not assessed. This analysis does not
include a direct comparison group of patients treated
endoscopically.
CONCLUSIONS
Both esophagectomy and endoscopic therapy may inad-
vertently harm patients with intramucosal esophageal ade-
nocarcinoma, requiring concerted attempts to improve the
safety of both therapies. Esophagectomy is more successful
and effective in this setting than endoscopic therapies, but it
is not as safe. Treatment decisions require balancing harm
with ineffective cancer treatment. It is critical to carefully
prescribe therapy on the basis of treatment goals, cancer
characteristics, and patient characteristics. Esophagectomy
is best for patients in whom complete and durable eradica-
tion of the cancer is paramount and in whom esophagec-
tomy is a low-risk procedure. Endoscopic therapy is best
for patients in whom the risk of esophagectomy outweighs
the need for freedom from cancer. Choice of endoscopic
therapy requires adequate esophageal function, that is, is
the esophagus worth saving? Choice of esophagectomy re-
quires meticulous patient preparation and fastidious surgi-
cal technique. Unfortunately, it has been reported that
a major determinant of therapy in patients with these can-
cers is who performs the first evaluation: a surgeon or
a gastroenterologist.14
I will prescribe regimens for the good of my patients
according to my ability and my judgment and never
do harm to anyone.
—Hippocratic OathReferences
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FIGURE E1. Nomogram of 5-year survival after esophagectomy for in-
tramucosal esophageal adenocarcinoma according to lung function and
age at operation based on model 1 in Table 4. Dashed lines are equivalent
to 1 standard error of the predicted value. A, Lung function. Values for
other risk factors were set as follows: age ¼ 65 years and length of
cancer¼ 1.4 mm. B, Age. Values for other risk factors were set as follows:
forced vital capacity (percent of predicted)¼ 95 and length of cancer¼ 1.4
mm. FVC, Forced vital capacity.
FIGURE E2. Nomogram for multivariable equation in Table 4. Predicted
mortality at 5 years by pathologic tumor depth. Values for other risk factors
were set as follows: age ¼ 65 years, forced vital capacity (percent of
predicted) ¼ 95, no hiatal hernia, no esophageal cancer recurrence, no
new primary cancer. Dashed lines are equivalent to 1 standard error of
the predicted value.
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TABLE E1. Interplay among cancer characteristics
Characteristic
Depth of invasion
P
LP (n ¼ 50)
no. (%)
MM1 (n ¼ 42)
no. (%)
MM2 (n ¼ 16)
no. (%)
MM3 (n ¼ 56)
no. (%)
Barrett esophagus 43 (86) 37 (88) 15 (94) 56 (100) .005
Cancer size on EGD
Length (cm), median (range) 0.3 (0-4.5) 0.4 (0-4) 0.8 (0-5.5) 1 (0-10) .002
Width (cm), median (range)* 0.3 (0-7.5) 0.1 (0-7.5) 0.6 (0-2.5) 0.6 (0-4.6) .01
Area (cm2), median (range)* 0.1 (0-30) 0 (0-30) 0.4 (0-14) 0.5 (0-32) .008
Cancer size on pathology
Length (cm), median (range)y 0.4 (0.1-2.0) 0.7 (0.1-2.0) 0.6 (0.1-5.5) 1.2 (0.3-5.9) <.001
Depth (mm), median (range)z 0.5 (0.2-2.0) 1.0 (0.4-4.0) 1.0 (0.5-4.5) 1.8 (0.1-9.0) <.001
Clinical stage .02
cHGD 12 (24) 8 (19) 1 (6.2) 7 (12)
cT1 33 (66) 31 (74) 14 (88) 37 (66)
>cT1 5 (10) 3 (7.1) 1 (6.2) 12 (21)
Pathologic stage <.001
IA 48 (96) 38 (90) 14 (88) 38 (68)
IB 2 (4.0) 4 (9.5) 2 (12) 17 (30)
IIIA 0 (0) 0 (0) 0 (0) 1 (1.8)
Histologic grade <.001
G1 24 (48) 16 (38) 3 (19) 12 (21)
G2 24 (48) 22 (52) 11 (69) 26 (46)
G3 2 (4.0) 4 (9.5) 2 (12) 18 (32)
Lymphovascular invasion <.001
Yes 0 (0) 0 (0) 0 (0) 6 (11)
Possible 0 (0) 3 (7.3) 3 (19) 9 (17)
No 43 (100) 38 (93) 13 (81) 39 (72)
LP, Lamina propria,MM,muscularis mucosa;MM1, inner;MM2, between;MM3, outer; EGD, esophagogastroduodenoscopy; cHGD, clinical high-grade dysplasia. *n¼ 50, 40,
15, and 50, respectively. yn ¼ 43, 42, 16, and 55, respectively. zn ¼ 42, 42, 16, and 55, respectively.
APPENDIX E1. Clinical and pathologic stage
Pathologic stage
Clinical stage
cT1N0* cT1bxN0y
<pT1N0M0 12 17
pT1aN0M0 65 48
pT1aNþM0z 0 0
pT1bN0M0 43 14
pT1bNþM0 7 3
>pT1N0M0 6 21
>pT1NþM0 4 82
>pT1N0M1 0 1
>pT1NþM1 0 5
Total 137 191
Of 1357 esophagectomies between January 1983 and January 2010, 1149 were for
adenocarcinoma; 722 patients had no induction therapy. Distribution of pathologic
stage cT1N0 patients is shown. *cT1 includes both intramucosal (cT1a) and submu-
cosal cancers (cT1b). yEndoscopic ultrasound was noninformative, so preoperative
biopsy was used to determine clinical stage. zNþ indicates regional lymph node
metastases.
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APPENDIX E2. Variables considered in multivariable analyses
Demographic Age (y), sex
Pulmonary function FEV1 (percent of predicted), FVC (percent of predicted)
Esophagus Barrett esophagus, Barrett surveillance, hiatal hernia, hiatal hernia length (cm)
Cancer Prior cancer; pathologic tumor length (cm), depth (cm), and location (LP, MM1, MM2, MM3); histologic grade
(G1, G2, G3); site of anastomosis (neck, chest); pathologic staging (LP, MM1, MM2, MM3, G1, G2, G3);
cHGD; total number of nodes sampled
Surgical approach Thoracotomy, transhiatal
Postoperative complications Anastomotic leak, respiratory failure, vocal cord paralysis, wound infection, deep vein thrombosis, atrial fibrillation,
pleural effusion, pneumothorax, pneumonia
Future complications New primary cancer, time to new primary cancer, recurrence of esophageal cancer, time to recurrence of
esophageal cancer
Experience Years since January 1, 1983
FEV1, Forced expiratory volume in 1 second; FVC, forced vital capacity, LP, lamina propria,MM,muscularis mucosa;MM1, inner;MM2, between;MM3, outer; cHGD, clinical
high-grade dysplasia.
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